A Postmarket Surveillance Registry of the BioMatrix Drug-eluting Stent

Trial Profile

A Postmarket Surveillance Registry of the BioMatrix Drug-eluting Stent

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms eBMX-PMS
  • Sponsors Biosensors International Group
  • Most Recent Events

    • 21 May 2013 New registry data were presented at EuroPCR 2013, according to a Biosensors International Group.
    • 20 May 2011 Results have been presented for the first time at EuroPCR-2011 according to a Biosensors International Group media release; results were also reported in the media release.
    • 14 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top